INDV (Indivior Pharmaceuticals) Notes Receivable: $0 Mil (As of Mar. 2026)


INDV Indivior Pharmaceuticals Inc INDV
69 GF Score
Price $41.82
GF Value $22.98
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Indivior Pharmaceuticals Notes Receivable?

Indivior Pharmaceuticals INDV +1.31% 69 Notes Receivable is $0 Mil as of Mar. 2026. GuruFocus rates INDV with a GF Score™ of 69/100 and a GF Value™ of $22.98 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Indivior Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2026 was $0 Mil.

Indivior Pharmaceuticals Notes Receivable Related Terms

Indivior Pharmaceuticals Notes Receivable Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Notes Receivable Chart

Indivior Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Indivior Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INDV
69GF Score
Indivior Pharmaceuticals Inc INDV
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indivior Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0 Mil mean?
Indivior Pharmaceuticals (INDV) has a Notes Receivable of $0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Indivior Pharmaceuticals and its competitors.
Is Indivior Pharmaceuticals' Notes Receivable too high?
Indivior Pharmaceuticals' current Notes Receivable is $0 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' Notes Receivable compare to AMRX and KNSA?
Indivior Pharmaceuticals' Notes Receivable of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Notes Receivable is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.98, compared to a current price of $41.82 — trading 82% above its estimated fair value. The current Notes Receivable is $0 Mil. Indivior Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Notes Receivable is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $41.82 is trading 82% above its estimated GF Value™ of $22.98. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

  • Notes Receivable: $0 Mil
  • GF Value™: $22.98 vs. price of $41.82 (82% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Other Exchanges E7P:Germany
Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
69GF Score

Get the complete analysis for INDV

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.82
Price
$22.98
GF Value